XML 34 R24.htm IDEA: XBRL DOCUMENT v3.25.1

Collaboration Agreements, License Agreement and Revenues (Tables)

3 Months Ended

Mar. 31, 2025

Schedule of Drug Product Revenue

Drug product revenue from commercial-grade active pharmaceutical ingredient (“API”) or bulk drug product sales to Astellas and AstraZeneca was as follows for the three months ended March 31, 2025 and 2024 (in thousands):

		Three Months Ended March 31,
		2025				2024
Astellas Japan Agreement		$	1,781			$	(2,205	)
Astellas Europe Agreement			814				1,021
AstraZeneca U.S./RoW Agreement			—				25,670
Drug product revenue, net		$	2,595			$	24,486

Drug Product Revenue, Net [Member]

Roll-forward of Related Contract Liabilities

The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands):

		Balance at December 31, 2024				Recognized as Revenue				Reclassified to Accrued Liability / Accounts Payable				Balance at March 31, 2025
Drug product revenue - deferred revenue:
Astellas Europe Agreement		$	(9,901	)		$	814			$	2,076			$	(7,011	)

AstraZeneca Agreements [Member]

Roll-forward of Related Contract Liabilities

The following table includes a roll-forward of the related deferred revenue that is considered as a contract liability (in thousands):

		Balance at December 31, 2024				Additions				Recognized as Revenue (Discontinued Operations)				Currency Translation and Other				Balance at March 31, 2025
AstraZeneca China performance obligation    - deferred revenue		$	(132,097	)		$	(35,363	)		$	36,863			$	(248	)		$	(130,845	)

X

- Definition

Schedule of drug product revenue.

+ References

No definition available.

+ Details

Name:	fgen_ScheduleOfDrugProductRevenueTableTextBlock
Namespace Prefix:	fgen_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=fgen_DrugProductRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: